Medically reviewed by Jay N. Yepuri, MD MASH is the new term for NASH. MASH stands for metabolic dysfunction–associated ...

Nonalcoholic steatohepatitis (NASH) is a type of nonalcoholic fatty liver disease (NAFLD). It involves a buildup of fat in your liver, inflammation, and damage. Nonalcoholic steatohepatitis (NASH ...

NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused ...

but other risk factors make it possible to develop liver disease even if you drink little to no alcohol. Non-alcoholic steatohepatitis (NASH) is a condition that falls under the umbrella of ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

The FDA turned down an Intercept Pharmaceuticals drug application for the fatty liver disease NASH, a decision that comes nearly three years after the regulator first rejected the molecule.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Resmetirom is the first FDA-approved drug for NASH with liver fibrosis, offering a new treatment option alongside lifestyle changes. Clinical trials demonstrated significant NASH resolution and ...

If ignored, NAFLD can progress to more serious conditions like NASH, cirrhosis, and potentially liver cancer. Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that appears when ...